Weiheng Chen

Weiheng Chen is a senior partner at Wilson Sonsini Goodrich & Rosati, where he heads the firm's Greater China practice.

Weiheng's practice is focused on cross-border mergers and acquisitions, private equity, and capital markets transactions in Asia. He has represented clients in connection with some of the largest and most significant M&A and capital market deals in a variety of industries, including technology, media and telecom, healthcare, education, consumer, and financial institutions. He also has worked on a large number of private equity and venture capital investment, going-private, joint venture, and restructuring transactions involving private equity and venture capital firms and multinational corporations. In addition, Weiheng has advised on many high-profile securities offerings, including Hong Kong IPOs and HKSE listings, and SEC-registered offerings and NYSE and NASDAQ listings. He has extensive experience representing both issuers and underwriters.

• Represented WuXi Biologics and WuXi AppTec in the US$527 million Hong Kong spin-off IPO of WuXi XDC
• Represented Lumentum in the $750 million acquisition of Cloud Light Technology Group
• Represented Boyu Capital in the acquisition of Quasar Medical
• Represented PW Medtech and the acquisition consortium in the $4.6 million going-private transaction of China Biologic Products, Inc.
• Represented Warburg Pincus and the acquisition consortium in the $9.7 billion going-private transaction of 58.com

• M&A
• Capital markets: Equity
• Restructuring and insolvency
• Private equity
• Private equity funds

• Healthcare
• Pharma and life sciences
• Tech and telecoms
• Consumer goods and services
• Government and public policy

• Hong Kong
• New York

• ABA
• Hong Kong Law Society

• LL.M., Harvard Law School
• Master of Jurisprudence and LL.B., Peking University Law School